Gas6 induces inflammation and reduces plaque burden but worsens behavior in a sex-dependent manner in the APP/PS1 model of Alzheimer’s disease
Open Access
- 7 February 2022
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 19 (1) , 1-17
Abstract
Background: Alzheimer’s disease is the leading cause of dementia worldwide. TAM receptor tyrosine kinases (Tyro3, Axl, MerTK) are known for their role in engagement of phagocytosis and modulation of inflammation, and recent evidence suggests a complex relationship between Axl, Mer, and microglial phagocytosis of amyloid plaques in AD. Gas6, the primary CNS TAM ligand, reduces neuroinflammation and improves outcomes in murine models of CNS disease. Therefore, we hypothesized that AAV-mediated overexpression of Gas6 would alleviate plaque pathology, reduce neuroinflammation, and improve behavior in the APP/PS1 model of Alzheimer’s disease. Methods: Adeno-associated viral vectors were used to overexpress Gas6 in the APP/PS1 model of Alzheimer’s disease. Nine-month-old male and female APP/PS1 and nontransgenic littermates received bilateral stereotactic hippocampal injections of AAV-Gas6 or AAV-control, which expresses a non-functional Gas6 protein. One month after injections, mice underwent a battery of behavioral tasks to assess cognitive function and brains were processed for immunohistochemical and transcriptional analyses. Results: Gas6 overexpression reduced plaque burden in male APP/PS1 mice. However, contrary to our hypothesis, Gas6 increased pro-inflammatory microglial gene expression and worsened contextual fear conditioning compared to control-treated mice. Gas6 overexpression appeared to have no effect on phagocytic mechanisms in vitro or in vivo as measured by CD68 immunohistochemistry, microglial methoxy-04 uptake, and primary microglial uptake of fluorescent fibrillar amyloid beta. Conclusion: Our data describes a triad of worsened behavior, reduced plaque number, and an increase in proinflammatory signaling in a sex-specific manner. While Gas6 has historically induced anti-inflammatory signatures in the peripheral nervous system, our data suggest an alternative, proinflammatory role in the context of Alzheimer’s disease pathology.Keywords
Funding Information
- National Institute on Aging (F30AG061939)
- National Institutes of Health (R01 AG030149, R56 AG066397)
- School of Medicine and Dentistry, University of Rochester (University Research Award)
- National Institute of General Medical Sciences (T32 GM007356)
This publication has 49 references indexed in Scilit:
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Plasma Based Markers of [11C] PiB-PET Brain Amyloid BurdenPLOS ONE, 2012
- Involvement of Receptor Tyrosine Kinase Tyro3 in Amyloidogenic APP Processing and β-Amyloid Deposition in Alzheimer's Disease ModelsPLOS ONE, 2012
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Chronic IL-1β-Mediated Neuroinflammation Mitigates Amyloid Pathology in a Mouse Model of Alzheimer’s Disease without Inducing Overt NeurodegenerationJournal of Neuroimmune Pharmacology, 2011
- GAS6 Enhances Repair Following Cuprizone-Induced DemyelinationPLOS ONE, 2010
- Functional Crosstalk between Type I and II Interferon through the Regulated Expression of STAT1PLOS Biology, 2010
- The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspectiveJournal of Neuroinflammation, 2008
- Regulation of Microglial Phagocytosis and Inflammatory Gene Expression by Gas6 Acting on the Axl/Mer Family of Tyrosine KinasesJournal of Neuroimmune Pharmacology, 2007
- Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathologyJournal of Clinical Investigation, 2007